Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)

Genetic cardiomyopathies are disorders of the cardiac muscle, most often explained by pathogenic mutations in genes encoding sarcomere, cytoskeleton, or ion channel proteins. Clinical phenotypes such as heart failure and arrhythmia are classically treated with generic drugs, but aetiology-specific a...

Full description

Bibliographic Details
Main Authors:	Backs, J. (Author), Carrier, L. (Author), Coats, A.J.S (Author), de Boer, R.A (Author), Dimmeler, S. (Author), Eschenhagen, T. (Author), Filippatos, G. (Author), Gepstein, L. (Author), Heymans, S. (Author), Hulot, J.-S (Author), Knöll, R. (Author), Kupatt, C. (Author), Linke, W.A (Author), Seferovic, P.M (Author), Seidman, C.E (Author), Thum, T. (Author), Tocchetti, C.G (Author), van der Velden, J. (Author), Walsh, R. (Author)
Format:	Article
Language:	English
Published:	John Wiley and Sons Ltd 2022
Subjects:	Cardiomyopathy Dilated cardiomyopathy Disease mechanism Gene therapy Heart failure Hypertrophic cardiomyopathy Molecular biology Pharmacology
Online Access:	View Fulltext in Publisher

Internet

View Fulltext in Publisher

Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)

Internet

Similar Items